The prevalence of psoriasis in Trabzon

Yaylı, Savaş; Topbaş, Murat; Arıca, Deniz Aksu; Tuğcigil, Sibel; Çapkın, Erhan; Bahadır, Sevgi

doi:10.4274/turkderm.75735

Cited by 5 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this study was conducted in adolescents (age 12–20 years). Likewise, for adults, several studies found higher prevalence rates in men than in women,20,27,28,56–64 but other studies reported contrasting findings (Table S6; see Supporting Information) 14,21,22,29,65–71…”

Section: Resultsmentioning

confidence: 99%

“…Likewise, for adults, several studies found higher prevalence rates in men than in women, 20,27,28,[56][57][58][59][60][61][62][63][64] but other studies reported contrasting findings (Table S6; see Supporting Information). 14,21,22,29,[65][66][67][68][69][70][71] When examining variation in psoriasis prevalence between genders for all ages, the majority of the studies reported a higher prevalence rate in male than in female patients. 16,18,23,24,30,33,34,[36][37][38]40,51,[72][73][74][75][76][77][78][79][80][81] However, studies from Denmark, 31 Norway, 17,25,…”

Section: Variation In Incidence and Prevalence By Agementioning

confidence: 99%

“…19 In adults, some studies showed a trend of increasing psoriasis prevalence with age up to either 20-29 or 30-39 years of age, which then decreased at the age of 40-49 years, before it increased again with a second peak at around either 50-59 or 60-69 years of age. [20][21][22][23][24][25][26] However, most studies reported an increasing trend with age until around 60 or 70 years, after which the prevalence decreased (Table S4). 14,15,18,[27][28][29][30][31][32][33][34][35][36][37][38][39][40] Variation in incidence and prevalence by gender In children, although the overall incidence rate was lower in boys than in girls (37Á9 vs. 43Á9 per 100 000 person-years, respectively), this pattern was not consistent across all age bands (Table 1).…”

Section: Variation In Incidence and Prevalence By Agementioning

confidence: 99%

See 2 more Smart Citations

Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*

et al. 2020

View full text Add to dashboard Cite

Summary Background There is a lack of any overview of changes over time and variation in the epidemiology of psoriasis with age and between genders. Objectives To perform a systematic review of published population‐based studies on variations in psoriasis incidence and prevalence with age and between genders, and to explore trends in psoriasis epidemiology over time. Methods Eleven electronic and regional databases were searched from their inception dates to October 2019. No language restrictions were applied. Studies were eligible if they reported on changes in psoriasis incidence and/or prevalence over time and/or by age group and gender. Results In total 308 papers were critically appraised, from which 90 studies from 22 countries were included. Incidence data confirmed a clear bimodal age pattern in psoriasis onset, with the first and second peaks at around 30–39 and 60–69 years of age, respectively, and evidence suggesting that it presents slightly earlier in women than in men. Prevalence data showed an increasing trend with age until around 60 or 70 years, after which it decreases. Although there was lack of agreement on specific gender differences in psoriasis incidence and prevalence, a slight male predominance was reported in several studies. Studies worldwide suggested a stable or slightly decreasing trend in psoriasis incidence, while an increasing trend in psoriasis prevalence has been consistently reported. One particular challenge faced was the vastly different methodologies used in the included studies, which contributed to some of the heterogeneity of the results. Conclusions Studies on changes over time in the occurrence of psoriasis have contributed to a greater appreciation of the increasing burden of the disease. However, further research is required to determine the reasons driving the increase in psoriasis prevalence over time.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Variation In Incidence and Prevalence By Agementioning

confidence: 99%

Section: Variation In Incidence and Prevalence By Agementioning

confidence: 99%

See 1 more Smart Citation

Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Psoriasis is a chronic inflammatory skin disease that affects 2%-4% of the general population [21,22]. The prevalence of MS has been reported to be35% in the United States [21].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Metabolic Syndrome and Its Parameters and Their Correlations With Psoriasis Duration, Severity, and Sleep Quality In Psoriasis Patients: A Cross-Sectional Study

Taş

Kabeloğlu

2021

Dermatol Pract Concept

View full text Add to dashboard Cite

Background: Psoriasis is an inflammatory skin disease that may lead to comorbidities, including metabolic syndrome (MS). Objective: We determined the prevalence of MS and its correlation with psoriasis duration, severity, and sleep quality in psoriasis patients. Methods: A total of 112 subjects with chronic plaque psoriasis were studied. Demographics, MS parameters, disease duration, severity, and sleep quality were examined. The Psoriasis Area and Severity Index (PASI)and the Pittsburgh Sleep Quality Index (PSQI) were used to assess psoriasis severity and sleep quality, respectively. Presence of MS and its correlations with psoriasis duration, severity and sleep quality were investigated. Results: Of 112 patients, 76 (67.8%) were diagnosed with MS. Of all patients, 74.1% had a high PASI, and 84.8% had a high PSQI. The mean values of psoriasis duration, body mass index, waist circumference, fasting glucose, HOMA-IR, triglyceride levels, blood pressure, PSQI, sleep latency, and daytime sleep dysfunction were significantly higher in the MS group than non-MS group, whereas the mean HDL level was lower. The prevalences of MS, high fasting glucose, and low HDL were significantly higher among female, but not male, patients with severe psoriasis (PASI >10) than those without severe psoriasis. Disease duration, high body mass index, waist circumference, blood pressure, fasting glucose, HOMA-IR, triglyceride levels, low HDL, and poor sleep quality were significantly correlated with the presence of MS. However, only waist circumference, fasting glucose, blood pressure, and low HDL were predictive of the development of MS. Conclusions: MS is common among psoriasis patients, and especially in females with advanced psoriasis, high fasting glucose, and low HDL levels. Besides diagnostic criteria of MS, a long duration of psoriasis, poor sleep quality and high-HOMA-IR correlate with the development of MS. High fasting glucose and low HDL levels may facilitate MS development in association with psoriasis severity in females.

show abstract

“…Despite various studies reporting that the incidence of psoriasis is higher either in females or males [ 33 ], there is a theoretical consensus on no gender discrimination in psoriasis incidence [ 6 ]. In a study on the incidence of psoriasis in Turkey, the prevalence of the disease is given as 1.2% in females and as 1.0% in males [ 69 ]. In another study, the female/male ratio in Turkish psoriasis patients has been reported as 200/129 [ 70 ].…”

Section: Discussionmentioning

confidence: 99%

NAT2Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris

Dursun

Zamani

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Psoriasis is a common, chronic, and autoimmune skin disease. Factors that play a role in etiopathogenesis of psoriasis include internal factors such as genetic susceptibility and immunological factors and external factors such as stress, infection, trauma, drug, and environmental compounds. N-acetyltransferase 2 (NAT2) is a xenobiotic enzyme that is involved in the metabolism of drugs, environmental toxins, and carcinogens. In this study, we aimed to demonstrate whether the variations in the NAT2 gene lead to a predisposition to psoriasis by affecting the enzyme's ability to metabolize drugs and environmental components or not. Three polymorphisms (rs1799929, rs1799930, and rs1799931) in NAT2 gene were genotyped and compared by real-time PCR method in 260 psoriasis vulgaris patients and 200 healthy controls. There was no difference in the genotype distributions and allele frequencies of polymorphisms between psoriasis vulgaris patients and controls. When the effects of polymorphisms on the clinical features of the disease, such as onset age and severity, are assessed, it has been found that rs1799930 and rs1799929 are, respectively, associated with early onset age and severity of the disease. In conclusion, rs1799929, rs1799930, and rs1799931 polymorphisms of the NAT-2 gene do not appear to be a risk factor for the development of psoriasis. Conversely, they may have an effect on either more severe or early onset cases of the disease.

show abstract

The prevalence of psoriasis in Trabzon

Cited by 5 publications

References 13 publications

Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*

Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*

Prevalence of Metabolic Syndrome and Its Parameters and Their Correlations With Psoriasis Duration, Severity, and Sleep Quality In Psoriasis Patients: A Cross-Sectional Study

NAT2Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris

Contact Info

Product

Resources

About